EYP-1901 for Wet Age-Related Macular Degeneration

Phase 3 LUCIA (NCT06683742) is non-inferiority design vs aflibercept with 6-month redosing, informed by positive Phase 2 DAVIO 2 which met BCVA non-inferiority endpoint. NI trials for sustained-release anti-VEGF have mixed Phase 3 outcomes (e.g., Susvimo succeeded; KSI-301 failed). DAVIO 2 results support efficacy but Phase 3 redosing schedule differs and treatment-naive inclusion adds risk. FDA-aligned NI margin design is favorable. Modest edge over coin-flip.s

Phase 3 and active-not-recruiting status lower execution risk, and BCVA at 52/56 weeks is a standard, objective AMD endpoint. But an active aflibercept comparator sets a high efficacy bar for a sustained-delivery injection, with no prior data provided to de-risk noninferiority/superiority.

Phase 3 head-to-head vs aflibercept; standard objective BCVA endpoint at 1 year; active not recruiting, on track for Oct 2026 readout; no design red flags; ophthalmology Phase 3 trials have moderate historical success odds.

EYP-1901 showed statistical non-inferiority to aflibercept in the Phase 2 DAVIO 2 trial with a minimal -0.3 to -0.4 letter difference. The Phase 3 LUCIA trial utilizes a 3-dose aflibercept loading phase before randomization and allows supplemental rescue injections if disease activity returns. This rescue protocol strongly protects the BCVA primary non-inferiority endpoint. With large sample sizes (N=475) providing high statistical power, a positive result is highly probable.

Phase 2 DAVIO 2 met non-inferiority on BCVA with similar design and margin. Phase 3 LUGANO uses same endpoint; typical Phase 3 success after positive Phase 2 in wet AMD is ~65%. Risk: longer follow-up, larger sample, but strong prior data.

Phase 3 non-inferiority trial vs aflibercept in wet AMD. Phase 2 DAVIO showed +3.2 letters at 6mo with zero rescue, but small sample (n~18/arm). Sustained 12-month BCVA non-inferiority is harder; TKI mechanism less proven than anti-VEGF antibodies. Durasert platform validated in other indications but release kinetics variability is a risk. Phase 3 ophthalmology non-inferiority trials have ~45-50% success rate with good Phase 2 data. Slightly below even odds.

EYP-1901's Durasert technology enables sustained delivery, potentially matching aflibercept efficacy with reduced burden. Phase 2 data showed non-inferiority trends. Wet AMD is a validated target; if safety holds, non-inferiority on BCVA is plausible given mechanism parity with anti-VEGF standards.

Phase 3 head‑to‑head against aflibercept in wet AMD sets a high efficacy bar. No disclosed prior Phase 2 data suggests modest advantage. Endpoint (BCVA change at 52‑56 weeks) is stringent, and the trial is still active not recruiting, implying no interim signals. These factors point to a sub‑50% chance of a positive result.

Wet AMD is a well-established indication with multiple approved therapies (aflibercept, ranibizumab, faricimab). EYP-1901 is a sustained-release vorolanib implant, but Phase 2 data showed mixed results with safety concerns including cataracts and endophthalmitis. The Phase 3 DAVIO 3 trial uses an active comparator (aflibercept), making superiority difficult. The primary endpoint at Weeks 52/56 requires durable efficacy against a high standard of care. EyePoint's prior Phase 3 failures in uveitis raise execution risk. Current status 'Active Not Recruiting' with 127 days to completion suggests ~

Phase 3 wet AMD trial comparing to established standard (aflibercept) using BCVA gold-standard endpoint; sustained-release delivery is differentiated but requires robust non-inferiority; wet AMD Phase 3 trials have favorable track record given validated mechanism.